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Abstract
Cell permeabilization by electric pulses (EP), or electroporation, is widely used for intracellular delivery of drugs and plasmids, as well as for
tumour and tissue ablation. We found that cells pre-treated with 100-ls EP develop delayed hypersensitivity to subsequent EP applications.
Sensitizing B16 and CHO cells by splitting a single train of eight 100-ls EP into two trains of four EP each (with 5-min. interval) decreased the
LD50 1.5–2 times. Sensitization profoundly enhanced the electroporation-assisted uptake of bleomycin, a cell-impermeable cytotoxic agent
accepted for killing tumours by electrochemotherapy. EP exposures that were not lethal per se caused cell death in the presence of bleomycin
and proportionally to its concentration. Sensitizing cells by a split-dose EP exposure increased bleomycin-mediated lethality to the same extent
as a 10-fold increase in bleomycin concentration when using a single EP dose. Likewise, sensitization by a split-dose EP exposure (without
changing the overall dose, pulse number, or amplitude) enhanced the electroporative uptake of propidium up to fivefold. Enhancement of the
electroporative uptake appears a key mechanism of electrosensitization and may benefit electrochemotherapy and numerous applications that
employ EP for cell permeabilization.
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Introduction
Electropermeabilization by intense electric pulses (EP), also com-
monly known as electroporation is a well-established physical method
of disrupting cell membrane, to kill cells or to facilitate the uptake of
membrane-impermeable substances without cell killing [1–4]. This
method is central for many existing and emergent medical applica-
tions, including tissue and tumour ablation by irreversible electropo-
ration (IRE) [2, 4–7], electrochemotherapy (ECT) [4, 8–11], gene
electrotransfer [12–17], and decellularization of transplants [18].
Recently, we found that cells subjected to electroporation develop
delayed sensitization to EP, and that the cytotoxic effect can be mark-
edly increased by splitting a single EP treatment into two fractions
[19]. The cell death increases because the first fraction not only
incurs cell damage but also induces delayed electrosensitization,
thereby profoundly enhancing the effect of the second fraction and of
the treatment as a whole. By engaging sensitization, the lethality in
EP-treated cells could be increased from 0% to 90%, or the exposure
dose could be reduced more than twofold without reducing the effect.
Thus far, sensitization has been reported in vitro for U937, Jurkat,
and CHO cells using EP of 60-ns to 9-ls duration, at 1.8–13.3 kV/cm.
However, the mechanism responsible for the phenomenon of sensiti-
zation has not been understood.
Contemplated mechanisms include cell swelling and plasma
membrane spreading; ATP leakage and exhaustion of membrane
repair resources; electrochemical generation of ROS and membrane
damage by ROS; entry of Ca2+ and triggering the respective intracellu-
lar cascades; and several others. The central question is whether the
membrane of sensitized cells is permeabilized more efficiently, allow-
ing greater uptake of substances (drugs, plasmids, siRNA) without
increasing the EP dose or intensity. If this is the case, engaging sensi-
tization by split-dose EP treatment protocols could benefit numerous
technologies that rely on electroporation for intracellular delivery and
medical applications such as ECT.
Electrochemotherapy exploits EP treatments which are sufficient
for cell membrane permeabilization, but cause little cell death per se.
ECT relies on the electroporative uptake of a cell-impermeable or
poorly permeable cytotoxic drug, such as bleomycin or cisplatin.
Local uptake of the drug in the area of EP application ensures elimina-
tion of dividing cells [8–11, 20–22]. More than 40 different types of
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tumours responded to ECT, including those incurable with chemo-
therapy and not suitable for excision surgery. In clinical applications,
ECT caused complete regression of 75–80% of treated nodules. The
established and clinically approved EP delivery protocol for ECT con-
sists of eight pulses of 100-ls duration, which are delivered at either
1 or 1000 Hz [8, 11].
Although EP treatments are minimally invasive and efficient, they
may cause severe pain, damage of healthy tissues surrounding the
ablation area, involuntary muscle contractions and heart fibrillation
[23–25]. Use of a split-dose protocol to sensitize cells could poten-
tially help to achieve the same electroporative drug uptake at lower
EP amplitude, thereby profoundly reducing the side effects while
maintaining the treatment efficiency. Below, we show that enhanced
membrane permeabilization accompanies electrosensitization and
likely constitutes its principle mechanism. We show that a split-dose
delivery of 100-ls EP efficiently caused electrosensitization in mela-
noma and epithelial cell models, and that the sensitized cells
responded to EP by profoundly higher electroporative uptake of bleo-
mycin. Likewise, electrosensitized cells displayed higher uptake of




CHO-K1 (Chinese hamster ovary) and B16.F10 (mouse melanoma)
cells were obtained from ATCC (Manassas, VA, USA) and grown in
humidified 5% CO2 in air in standard culture dishes. CHO cells were
propagated in AMEM medium supplemented with 100 IU/ml penicillin
and 0.1 lg/ml streptomycin. B16 cells were propagated in McCoy’s
5A medium supplemented with 0.01% gentamicin. Both growth
media contained 10% foetal bovine serum. The media and its compo-
nents were purchased from Mediatech Cellgro (Herdon, VA, USA)
except for serum (Atlanta Biologicals, Norcross, GA, USA).
EP exposure, dosimetry, and thermometry
The pulse duration, number of pulses and inter-pulse intervals were
set using an S88K stimulator (Grass Instruments Co., Quincy, MA,
USA). These pulses gated a custom-made high-voltage, low-output
impedance electroporator device, which replicated stimulator pulses
and delivered them to an electroporation cuvette with a cell sample.
In this study, we used nearly rectangular 100-ls pulses with 10-ms
interpulse interval, and delivered them either as a single train of eight
pulses (single dose), or as two trains of four pulses each (split dose).
These exposure parameters were chosen to match the standard ECT
protocol [8, 9, 11] as closely as was technically possible, to facilitate
possible translation of our results into clinical practice. For fraction-
ated exposures, the 50/50 split (4+4 pulses) and the 5 min. interval
between the fractions were suggested in our earlier study [19]. The
pulse shape and amplitude were monitored with a TDS3052B oscillo-
scope (Tektronix, Wilsonville, OR, USA). The E-field values were
obtained by dividing the mean pulse voltage (from 50 to 300 V) by
the width of the gap in the electroporation cuvette (1 mm). The
absorbed dose was calculated as the energy delivered to the sample
normalized to the mass of the sample [26]; the maximum tested dose
was 60 J/g.
All EP exposures were performed at a room temperature of 22–
24°C. Heating of cell samples by EP was measured with a fibre optic
ReFlex-4 thermometer (Nortech Fibronic, Quebec City, Quebec, Can-
ada). Because of the efficient heat dissipation from the cuvette, the
temperature of exposed samples did not exceed 37°C even at the
maximum EP dose.
EP Cytotoxicity
Cells were harvested during the exponential growth phase, pelleted by
mild centrifugation, and resuspended at 3 9 106 cells/ml in fresh
growth medium. The cell suspension was loaded into a pair of stan-
dard electroporation cuvettes (BioSmith Biotech, San Diego, CA,
USA) and exposed to EP within several minutes. Both cuvettes
received the same EP treatment, but it was split into two fractions for
one of the cuvettes. Although the single-dose exposure took less than
a second and the split-dose one took 5 min., both samples remained
in the cuvettes until both exposures were completed. Immediately
afterwards, the samples were aliquoted into microcentrifuge tubes
and diluted with the fresh growth medium to 0.15 9 106 cells/ml.
The experiment continued the same way with a next pair of cuvettes
and testing a different E-field, and so forth. In each experiment, differ-
ent E-field levels were tested in a random sequence; the first and the
last pair in each experiment were accompanied by a third cuvette that
was subjected to a sham exposure (control).
In each experiment, we tested five different E-field values (from 0
to 3 kV/cm). Upon the completion of all exposures, cells were asepti-
cally aliquoted from the tubes into a 96-well plate, in triplicates at
15 9 103 cells/well and incubated at 37°C with 5% CO2 in air. Cell
survival was measured using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (BioAssay Systems, Hay-
ward, CA, USA). At 20 hrs after the EP treatment, 10 ll of MTT
reagent was added to each well, and incubation continued for addi-
tional 3 hrs. Next, the medium from the wells was aspirated and
replaced with 100 ll DMSO, and the plate was placed on an orbital
shaker for 10 min. to dissolve blue formazan crystals. Absorbance at
570 nm was read using Synergy 2 microplate reader (BioTEK, Winoo-
ski, VT, USA), and the readings in EP-exposed samples were normal-
ized to the sham-exposed control.
Electroporative uptake of bleomycin
In a separate series of experiments, cells were subjected to single-
and split-dose EP exposures in the presence of different concentra-
tions of bleomycin. Lyophilized bleomycin (Sigma-Aldrich, St. Louis,
MO, USA) was dissolved in a phosphate-buffered saline (PBS) at
5 mg/ml (3.5 mM) and stored at 20°C. Bleomycin was added to the
ª 2012 The Authors. Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd. 155
J. Cell. Mol. Med. Vol 17, No 1, 2013
cell suspension immediately prior to exposures at the concentration
of 0.058, 0.54, 5.9, or 65 lM. The suspension was dispensed in three
electroporation cuvettes: one for a single-dose exposure, the second
one for a split-dose exposure, and the third cuvette served as a paral-
lel control (sham exposure). The single-dose exposure was always
performed before the split-dose exposure, which deliberately biased
the results towards possibly reduced effect of sensitization (dis-
cussed in more detail in the Results section). The E-field amplitude
was fixed at a low value of 1.5 kV/cm, which caused little or no cell
death in the absence of the drug. Immediately after the exposures,
the samples were aliquoted into microcentrifuge tubes and incubated
on a bench for additional 10 min., and then diluted 20-fold with the
fresh growth medium. The experiment continued the same way with a
next triplet and using the same E-field, but testing a different drug
concentration. In each experiment, different bleomycin concentrations
were tested in a random sequence, and were also alternated with the
controls where no drug was added. The cell survival was measured
next day by the MTT assay the same way as described above.
Electroporative uptake of propidium
On the day of the experiment, harvested cells were resuspended in a
fresh growth medium and dispensed into 35-mm Petri dishes
(0.6 9 106 cells in 2 ml). The dishes were moved to the incubator
for a minimum of 1 hr. Immediately prior to the experiment, cells
from one Petri dish were collected, pelleted, and resuspended in
0.6 ml of a physiological solution containing (in mM): 140 NaCl, 5.4
KCl, 2 CaCl2, 1.5 MgCl2, 10 glucose and 10 HEPES (pH 7.3,
300 mOsm/kg). Propidium (Pr) iodide was added to the suspension
at 20 lg/ml, and 140-ll samples were dispensed into three electro-
poration cuvettes. Exposures were performed the same way as
described in the previous section (single dose, split dose and sham
exposure). Immediately after the exposures, the samples were ali-
quoted in individual wells of a 96-well plate. Pr fluorescence (exc./
em.: 530/590 nm) was read every 5 min. for the next 30 min. with
the microplate reader. Pr uptake data were expressed as percentage
of the parallel positive control (a sample of the same cell suspension
lysed with 0.05 mg/ml digitonin). All chemicals were purchased from
Sigma-Aldrich.
Results and discussion
Split-dose protocol facilitates the cytotoxic effect
of 100-ls pulses
In both CHO and B16 cells, exposure to eight 100-ls pulses at 2 or
3 kV/cm significantly decreased the 24-hr cell survival (Fig. 1). Simi-
larly to what was reported previously for shorter EP [19, 27–29], cell
survival curves started with a ‘shoulder’ (no cell death), followed by
Fig. 1 Enhancement of the cytotoxic effect of 100-ls electric pulses (EP) by exposure fractionation. CHO cells (left panel) and B16 cells (right panel)
were exposed to eight pulses (100 Hz) delivered either as a single dose (8p) or a split dose (4p+4p) with 5-min. interval between two trains. The
graphs show cell survival (mean ± SE for three to six independent experiments) versus the dose for different EP treatments. Dashed lines are the
best fit data approximations using exponential function; shaded areas denote 95% confidence intervals. Cell survival was measured by MTT assay at
24 hrs post exposure. Legends show lethal dose values for elimination of 50% of cells (LD50) by the respective exposure protocols.
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an exponential decrease proportionally to the absorbed dose. The effi-
ciency of different EP treatments could be conveniently compared
using the width of the shoulder and the dose that killed 50% of cells
(LD50).
In CHO cells, using a split-dose protocol decreased LD50 1.5 times
(from 33 to 22 J/g) and reduced the shoulder from 22 to 8 J/g. In
B16 cells, the shoulder was not affected, but the LD50 was reduced
twofold. Overall, the enhancement of the cytotoxic effect by sensitiza-
tion was similar to what was reported previously in other cell lines
and using nanosecond-range EP [19].
Sensitization assists electroporative uptake of
bleomycin
In the absence of bleomycin, exposure to eight pulses at 1.5 kV/cm
caused no detectable cell killing (CHO cells) or decreased cell sur-
vival by just 5–10% (B16). When cells were similarly electroporated
in the presence of bleomycin, their survival was decreased propor-
tionally to the concentration of the drug in the medium (Fig. 2).
Notably, the survival of control cells that were not exposed to EP
was not reduced even by the highest concentration of bleomycin,
so the reduction in cell survival could be attributed completely
(CHO) or mostly (B16) to the electroporative uptake of this cyto-
toxic drug.
The split-dose EP exposure triggered profoundly higher bleomycin
uptake than the single dose. For example, with 5.9 lM of bleomycin
in the medium, sensitizing cells by the split-dose EP protocol
increased the bleomycin-mediated lethality to the same or greater
extent than was achieved by a single-dose exposure with 65 lM of
bleomycin. In other words, sensitization of cells resulted in more than
10-fold increase in the electroporative uptake of bleomycin without
changing the E-field or the number of pulses.
The split-dose exposure was more efficient even despite the fact
that during the first 5 min. of incubation with bleomycin the cells
were porated by only four EP and obviously were taking up lesser
drugs than the cells exposed to all eight pulses as a single dose.
For a fair comparison, the split-dose exposed cells should have
been incubated longer, but the exact additional time was impossible
to define. To be on the conservative side, we used the protocol
biased against the effect of sensitization (single-dose exposure first,
split-dose second), hoping that sensitization will be strong enough
to overcome the bias. Indeed, the data show that after receiving the
second EP fraction, the split-dose exposed cells accumulated more
than enough bleomycin to compensate for its lower uptake during
the first 5 min.
Sensitization facilitates early uptake of
propidium
Fluorescence detection of Pr uptake is a common method to distin-
guish live and dead cells; however, disruption of cell membrane by
electroporation may trigger transient uptake of the dye, which is not
necessarily indicative of the lethal cell damage. In electroporated
cells, the early uptake of Pr reflects the degree of membrane permea-
bilization. If the cell fails to repair the membrane, it swells until mem-
brane rupture and death, which is reflected by delayed (minutes)
acceleration in Pr uptake [19, 30].
Figure 3 shows that Pr uptake early after exposure was signifi-
cantly higher in cells exposed using the split-dose protocol. The dif-
ference from the single-dose exposure was particularly well seen with
the low E-field exposure (1.5 kV/cm), which caused little or no cell
death. These experiments were also designed conservatively (same
as described for bleomycin above), so the data in Fig. 3 actually
underestimate the impact of sensitization. Indeed, prior to the onset
Fig. 2 Sensitization of cells by a split-dose electric pulses (EP) delivery facilitates electroporative uptake of bleomycin. CHO cells (left panel) and
B16 cells (right panel) were exposed to eight, 100-ls pulses (100 Hz, 1.5 kV/cm), either as a single dose or as a split dose (two trains of four
pulses each with a 5-min. interval). The graphs show cell survival in 24 hrs after the treatment (mean ± SE, n = 3–5) Bleomycin was added to the
medium at concentrations shown in the graph. EP caused little cell death in the absence of bleomycin, but facilitated the drug uptake and cell death
proportionally to bleomycin concentrations. The split-dose exposure triggered significantly higher bleomycin uptake than the single dose (*P < 0.05,
**P < 0.01, 2-tailed paired t-test). See text for more details.
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of measurements, the single-dose exposed cells were taking up Pr for
about 8 min. after eight EP; the split-dose exposed cells were taking
up Pr for only 2 min. after eight EP, plus for 5 min. after the first four
EP (Fig. 3, inset). If the first train of four EP did not cause sensitiza-
tion, the Pr uptake in the split-dose exposed group would likely be
much lower than that in the single-dose group.
Summary: Enhanced electroporation as a key
feature of electrosensitization
Both in Pr and bleomycin experiments, the first train of four EP obvi-
ously caused weaker membrane permeabilization and less sub-
stance uptake than a similar train of eight EP. However, the second
train of four EP caused high substance uptake, which quickly over-
whelmed the previous 5-min. lag. These data suggest that it is more
efficient plasma membrane permeabilization that distinguishes sen-
sitized cells, and that this change in membrane properties is the
hallmark of sensitization. The sensitized membrane may respond to
EP by forming more pores, larger pores, slower pore resealing, or
any combination of the above. Future search for mechanisms
responsible for electrosensitization should be focused on how ‘prim-
ing’ of cells by EP modifies the plasma membrane to make it hyper-
sensitive to electroporation.
Even before the exact mechanisms of sensitization are estab-
lished, taking this phenomenon into account may benefit multiple EP
applications that rely on electroporation for intracellular delivery
(transfection by electroporation, gene electrotransfer, loading cells
with drugs and siRNA, etc.) To pick up just one, in this article we
focused on the EP protocols accepted for ECT and found that sensiti-
zation is promising for increasing the ECT efficiency while reducing
its side effects. This observation now needs to be extended to 3D cell
models and in vivo, along with further analysis of its underlying
mechanisms.
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Fig. 3 Enhancement of propidium (Pr) uptake by CHO cells by electrosensitization. The cells were exposed to eight, 100-ls pulses (100 Hz) at either
1.5 kV/cm (left panel) or 1.8 kV/cm (right). The treatment was performed either as a single dose or as a split dose (two trains of four pulses each
with a 5-min. interval). Pr fluorescence (mean ± SE, n = 3) was normalized to the value in a sample dialyzed with digitonin. The inset shows the
timeline of procedures in each of the plotted groups (‘8p’ and ‘4p’ show the approximate time of exposure to eight electric pulses (EP) and four EP,
respectively; horizontal lines denote the period of incubation with propidium iodide and the time interval when fluorescence was measured). The split
dose protocol caused significantly higher Pr uptake than a single dose for all time-points except 0 min. at 1.8 kV/cm (P < 0.05–0.0001, 2-tailed
paired t-test). See text for more detail.
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